--- title: "Citius Pharmaceuticals to Participate in September 2026 Investor Conferences | CTOR Stock News" type: "News" locale: "en" url: "https://longbridge.com/en/news/297916337.md" description: "Citius Pharmaceuticals (CTXR) announced that Chairman and CEO Leonard Mazur will present at two New York investor conferences in September 2026: the Moody Capital Solutions Conference (Sept 9-10) and the H.C. Wainwright Global Investment Conference (Sept 14-16). During these events, Mazur will discuss the company's business, recent developments, and one-on-one investor meetings. Key topics include the commercialization of LYMPHIR by subsidiary Citius Oncology and advancements in late-stage pipeline assets Mino-Lok and Halo-Lido." datetime: "2026-09-03T04:30:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/297916337.md) - [en](https://longbridge.com/en/news/297916337.md) - [zh-HK](https://longbridge.com/zh-HK/news/297916337.md) generator: "portal-rs" --- # Citius Pharmaceuticals to Participate in September 2026 Investor Conferences | CTOR Stock News Citius Pharmaceuticals (CTXR) announced that Chairman and CEO Leonard Mazur will present and host one-on-one investor meetings at two New York City investor conferences in September 2026. *Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference and Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference* , /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that Chairman and Chief Executive Officer Leonard Mazur will present and host one-on-one investor meetings at two upcoming investor conferences in New York City. During his presentations and investor meetings, Mr. Mazur will provide an overview of the Company's business and recent developments, including the ongoing commercialization of LYMPHIR® (denileukin diftitox-cxdl) by the Company's majority-owned subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR), and the continued advancement of the Company's late-stage pipeline. **Moody Capital Solutions Conference:** - **Conference:** Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference - **Dates:** September 9–10, 2026 - **Location:** The Westin New York Grand Central, New York, NY - **Presentation Date & Time:** Wednesday, September 9, 2026, 3:15 pm – 4:00 pm ET - **Webcast:** webcast link **H.C. Wainwright Conference:** - **Conference:** H.C. Wainwright 28th Annual Global Investment Conference - **Dates:** September 14–16, 2026 - **Location:** Lotte New York Palace Hotel, New York, NY - **Presentation Date & Time:** Tuesday, September 15, 2026, 2:00 pm – 2:30 pm ET - **Webcast:** webcast link Please note that the presentation dates and times are subject to change. Participants should refer to the final program agenda for up-to-date information. Investors interested in scheduling a one-on-one meeting with management should contact their conference representative or the Company's investor relations team. **About Citius Pharmaceuticals, Inc.** Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. Citius Pharma owns approximately 62% of Citius Oncology. In December 2025, Citius Oncology launched LYMPHIR, a targeted immunotherapy for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Citius Pharma's late-stage pipeline also includes Mino-Lok®, a catheter lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A pivotal Phase 3 trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com. **About Citius Oncology, Inc.** Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. For more information, please visit www.citiusonc.com. **Investor Contact:** Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 **Media Contact:** STiR-communications Greg Salsburg Greg@STiR-communications.com SOURCE Citius Pharmaceuticals, Inc. ### Related Stocks - [CTXR.US](https://longbridge.com/en/quote/CTXR.US.md) - [CTOR.US](https://longbridge.com/en/quote/CTOR.US.md) ## Related News & Research - [Dauch to Present at the 2026 Jefferies Global Industrials Conference on September 10 | DCH Stock News](https://longbridge.com/en/news/298072542.md) - [Anteris to Present at September Healthcare Investor Conferences | AVR Stock News](https://longbridge.com/en/news/297551725.md) - [TransMedics to Present at Upcoming September Investor Conferences | TMDX Stock News](https://longbridge.com/en/news/297556781.md) - [SABINE ROYALTY TRUST ANNOUNCES MONTHLY CASH DISTRIBUTION FOR SEPTEMBER 2026 | SBR Stock News](https://longbridge.com/en/news/298035870.md) - [Novavax to Participate in September Investor Conferences | NVAX Stock News](https://longbridge.com/en/news/297830700.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**